Darolutamide is a potent androgen receptor antagonist with strong efficacy in prostate cancer models

Allele-Specific Chromatin Recruitment and Therapeutic Vulnerabilities of ESR1 Activating Mutations

(2018) Rinath Jeselsohn et al.   CANCER CELL

Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer

(2018) David A. Quigley et al.   CELL

A Somatically Acquired Enhancer of the Androgen Receptor Is a Noncoding Driver in Advanced Prostate Cancer

(2018) David Y. Takeda et al.   CELL

Structural Alterations Driving Castration-Resistant Prostate Cancer Revealed by Linked-Read Genome Sequencing

(2018) Srinivas R. Viswanathan et al.   CELL

Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201)

(2018) Hendrik Borgmann et al.   EUROPEAN UROLOGY

Recent Advances in Prostate Cancer Treatment and Drug Discovery

(2018) Ekaterina Nevedomskaya et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

The long tail of oncogenic drivers in prostate cancer

(2018) Joshua Armenia et al.   NATURE GENETICS

Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer

(2018) Maha Hussain et al.   NEW ENGLAND JOURNAL OF MEDICINE

Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer

(2018) Matthew R. Smith et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical Development of Darolutamide: A Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer

(2018) Karim Fizazi et al.   Clinical Genitourinary Cancer

Darolutamide (ODM-201) for the treatment of prostate cancer

(2017) Neal D. Shore   EXPERT OPINION ON PHARMACOTHERAPY

Exploiting Epigenetic Alterations in Prostate Cancer

(2017) et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

CHD1 regulates cell fate determination by activation of differentiation-induced genes

(2017) Simon J. Baumgart et al.   NUCLEIC ACIDS RESEARCH

Structure of the homodimeric androgen receptor ligand-binding domain

(2017) Marta Nadal et al.   Nature Communications

The Effect of F877L and T878A Mutations on Androgen Receptor Response to Enzalutamide

(2016) Stefan Prekovic et al.   MOLECULAR CANCER THERAPEUTICS

Drug discovery in advanced prostate cancer: translating biology into therapy

(2016) Timothy A. Yap et al.   NATURE REVIEWS DRUG DISCOVERY

Androgen synthesis in prostate cancer: do all roads lead to Rome?

(2016) Ryan Stuchbery et al.   Nature Reviews Urology

Androgen receptor variation affects prostate cancer progression and drug resistance

(2016) Edel McCrea et al.   PHARMACOLOGICAL RESEARCH

BAY 1024767 blocks androgen receptor mutants found in castration-resistant prostate cancer patients

(2016) Tatsuo Sugawara et al.   Oncotarget

NanoLuc Complementation Reporter Optimized for Accurate Measurement of Protein Interactions in Cells

(2015) Andrew S. Dixon et al.   ACS Chemical Biology

Global cancer statistics, 2012

(2015) Lindsey A. Torre et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Integrative Clinical Genomics of Advanced Prostate Cancer

(2015) Dan Robinson et al.   CELL

Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies

(2015) Anu-Maarit Moilanen et al.   Scientific Reports

Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial

(2014) Karim Fizazi et al.   LANCET ONCOLOGY

SWISS-MODEL: modelling protein tertiary and quaternary structure using evolutionary information

(2014) Marco Biasini et al.   NUCLEIC ACIDS RESEARCH

Thioredoxin Reductase 1 Expression and Castration-recurrent Growth of Prostate Cancer

(2014) Swaroop S. Singh et al.   Translational Oncology

The Discovery of Novel Human Androgen Receptor Antagonist Chemotypes Using a Combined Pharmacophore Screening Procedure

(2013) Arnout Voet et al.   ChemMedChem

PELP1: A review of PELP1 interactions, signaling, and biology

(2013) Brian J. Girard et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

A Clinically Relevant Androgen Receptor Mutation Confers Resistance to Second-Generation Antiandrogens Enzalutamide and ARN-509

(2013) J. D. Joseph et al.   Cancer Discovery

ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment

(2012) N. J. Clegg et al.   CANCER RESEARCH

The Impact of Point Mutations in the Human Androgen Receptor: Classification of Mutations on the Basis of Transcriptional Activity

(2012) Colin W. Hay et al.   PLoS One

Features and development ofCoot

(2010) P. Emsley et al.   ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY

Nuclear Receptor-Coregulator Interaction Profiling Identifies TRIP3 as a Novel Peroxisome Proliferator-activated Receptor γ Cofactor

(2009) Arjen Koppen et al.   MOLECULAR & CELLULAR PROTEOMICS

Structural basis for nuclear receptor corepressor recruitment by antagonist-liganded androgen receptor

(2008) Myles C. Hodgson et al.   MOLECULAR CANCER THERAPEUTICS